[Skip to Content]
[Skip to Content Landing]
Other Articles
May 1950

CLINICAL OBSERVATIONS ON A NEW SULFONAMIDE (GANTRISIN®)

Author Affiliations

CHICAGO; SHREVEPORT, LA.
From the Children's Memorial Hospital and the Otho S. A. Sprague Memorial Institute Laboratories, Chicago.

Am J Dis Child. 1950;79(5):785-790. doi:10.1001/archpedi.1950.04040010802001
Abstract

G A N T R I S I N,® 3,4-dimethyl-5-sulfanilamido-isoxazole, formerly known as NU-445, is a new sulfonamide which has as its advantages a high degree of solubility and low toxicity. Because of its solubility, there is no crystallization in the urine except with doses that are much higher than would be used therapeutically.

Bryer and his associates1 reported that the acute toxicity of gantrisin® is low in white mice. They found the drug comparable to sulfadiazine in its ability to protect mice against beta hemolytic streptococcus and pneumococcus infections. It is not as effective as sulfadiazine in experimental infections in mice produced by Klebsiella pneumoniae. Neither compound was protective against experimental infection produced by Hemophilus influenzae, type B. Sarnoff2 reported neither crystalluria nor signs of renal irritation in 36 patients treated with gantrisin.® He observed that the amount of the drug entering into the spinal fluid of

First Page Preview View Large
First page PDF preview
First page PDF preview
×